Get the Stockscreener App
6.29
0.63%
-0.04
After Hours:
6.17
-0.12
-1.91%
Minerva Neurosciences Inc stock is traded at $6.29, with a volume of 64,107.
It is down -0.63% in the last 24 hours and up +45.60% over the past month.
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
See More
Previous Close:
$6.33
Open:
$6.22
24h Volume:
64,107
Relative Volume:
0.85
Market Cap:
$272.20M
Revenue:
-
Net Income/Loss:
$-33.65M
P/E Ratio:
-1.4135
EPS:
-4.45
Net Cash Flow:
$-20.83M
1W Performance:
+49.05%
1M Performance:
+45.60%
6M Performance:
+257.39%
1Y Performance:
+220.92%
1-Day Range:
$6.00
$6.35
1-Week Range:
$4.13
$6.47
52-Week Range:
$1.15
$12.46
Minerva Neurosciences Inc Stock (NERV) Company Profile
Name
Minerva Neurosciences Inc
Sector
Industry
Phone
617-600-7373
Address
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
6.29 | 273.93M | 0 | -33.65M | -20.83M | -4.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Initiated | BTIG Research | Buy |
| Oct-02-19 | Reiterated | Chardan Capital Markets | Buy |
| Sep-25-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-31-19 | Initiated | H.C. Wainwright | Buy |
| Sep-01-17 | Initiated | Citigroup | Buy |
| Mar-06-17 | Resumed | Jefferies | Buy |
| May-12-16 | Resumed | Jefferies | Buy |
View All
Minerva Neurosciences Inc Stock (NERV) Latest News
Minerva Neurosciences (NASDAQ:NERV) Stock Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Minerva Neurosciences Expands Board Amid Fundraising Effort - MSN
Market Wrap: Can Minerva Neurosciences Inc continue delivering strong returnsLayoff News & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Minerva Neurosciences Inc (NERV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV) and Verastem (VSTM) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV), Gossamer Bio (GOSS) and Merck & Company (MRK) - The Globe and Mail
Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for Schizophrenia - MarketBeat
Minerva Outlines Confirmatory Phase 3 Plan for Roluperidone - TipRanks
Buyout Rumor: Is Minerva Neurosciences Inc subject to activist investor interest2025 Trading Recap & Real-Time Stock Entry Alerts - baoquankhu1.vn
Is Minerva Neurosciences Inc. subject to activist investor interestRate Cut & Reliable Momentum Entry Alerts - mfd.ru
Stock Analysis: Can Minerva Neurosciences Inc be recession proofJuly 2025 Setups & Momentum Based Trading Ideas - baoquankhu1.vn
Can Minerva Neurosciences Inc. stock double in the next yearJuly 2025 PreEarnings & Community Consensus Picks - mfd.ru
Minerva Neurosciences (NASDAQ:NERV) Share Price Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat
Can Minerva Neurosciences Inc. stock outperform in a bear marketJuly 2025 Weekly Recap & Weekly Top Performers Watchlists - mfd.ru
Minerva Neurosciences to Host Virtual KOL Event to Discuss - GlobeNewswire
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 - Yahoo Finance
Highs Report: Is Minerva Neurosciences Inc trading at a discountJuly 2025 Price Swings & Fast Moving Market Watchlists - baoquankhu1.vn
Minerva Neurosciences (NASDAQ:NERV) Share Price Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat
Earnings Update: Can Minerva Neurosciences Inc stock double in the next yearFed Meeting & Free Long-Term Investment Growth Plans - baoquankhu1.vn
FOMO Trade: Will Minerva Neurosciences Inc benefit from seasonalityJuly 2025 Movers & Precise Entry and Exit Recommendations - baoquankhu1.vn
Downgrade Watch: Can Minerva Neurosciences Inc stock reach 100 price targetWeekly Investment Summary & Stepwise Trade Signal Guides - Bộ Nội Vụ
Gap Down: Will Minerva Neurosciences Inc 4MNA stock top growth indexes - Bộ Nội Vụ
Street Watch: Is Minerva Neurosciences Inc stock a top pick in earnings seasonVolume Spike & Real-Time Stock Movement Alerts - Bộ Nội Vụ
Wall Street Recap: Why analysts upgrade Minerva Neurosciences Inc. stock2025 Key Highlights & Verified Short-Term Trading Plans - Bộ Nội Vụ
Minerva Neurosciences (NASDAQ:NERV) Cut to Sell at Wall Street Zen - MarketBeat
What risks investors should watch in Minerva Neurosciences Inc. stockWeekly Profit Analysis & Consistent Profit Trade Alerts - Улправда
Is Minerva Neurosciences Inc. (4MNA) stock attractive for dividend growth2025 Trading Volume Trends & Long-Term Capital Growth Strategies - Улправда
Is Minerva Neurosciences Inc. stock attractive for hedge fundsJuly 2025 Technicals & Real-Time Buy Signal Notifications - Улправда
Why Minerva Neurosciences Inc. stock is in analyst buy zone2025 Analyst Calls & Long-Term Investment Growth Plans - Улправда
Is Minerva Neurosciences Inc. stock safe for conservative investorsJuly 2025 Retail & Reliable Trade Execution Plans - Улправда
Why Minerva Neurosciences Inc. stock is rated strong buyJuly 2025 Momentum & Consistent Return Investment Signals - Улправда
Will Minerva Neurosciences Inc. (4MNA) stock top growth indexes2025 Momentum Check & Reliable Momentum Entry Alerts - Улправда
Minerva Neurosciences (NASDAQ:NERV) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Minerva Neurosciences (NASDAQ:NERV) & UCB (OTCMKTS:UCBJY) Head to Head Analysis - Defense World
Working capital per share of Minerva Neurosciences Inc – MUN:4MNA - TradingView — Track All Markets
Gains Recap: Why Minerva Neurosciences Inc stock is in analyst buy zoneProduct Launch & Free Expert Verified Stock Movement Alerts - moha.gov.vn
MSN Money - MSN
Published on: 2025-12-26 01:20:46 - moha.gov.vn
Reviewing Xenetic Biosciences (NASDAQ:XBIO) and Minerva Neurosciences (NASDAQ:NERV) - Defense World
Minerva Neurosciences shareholders approve key governance measures - MSN
Minerva Neurosciences Shareholders Approve Key Governance Measures - TipRanks
Risks Report: Why Minerva Neurosciences Inc. (4MNA) stock stays resilientMarket Activity Summary & Free High Accuracy Swing Entry Alerts - Улправда
Movement Recap: Why analysts upgrade Minerva Neurosciences Inc. stock2025 Growth vs Value & AI Powered Market Entry Ideas - Улправда
How strong is Minerva Neurosciences Inc. stock revenue growthGold Moves & Weekly High Return Forecasts - Улправда
Why analysts upgrade Minerva Neurosciences Inc. stockIndex Update & Risk Controlled Swing Alerts - Улправда
Minerva Neurosciences Inc Stock (NERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):